undamentalytics Newsletter
Sign in

Zimmer Biomet key statistics and ratios

In fiscal 2025, Zimmer Biomet had return on equity of 5.6% and a net margin of 8.6%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2007Dec 20072008Dec 20082009Dec 20092010Dec 20102016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin19.8%20.6%17.5%14.1%4.0%23.2%−4.8%14.2%−2.3%5.9%3.3%13.8%11.8%8.6%9.5%
Return on equity14.2%15.3%12.7%10.5%4.0%16.9%−3.3%9.6%−1.1%3.2%1.9%8.4%7.2%5.6%6.4%
Return on assets—11.7%9.5%7.6%1.8%6.9%−1.5%4.6%−0.6%1.7%1.0%4.8%4.2%3.2%3.5%
Effective tax rate31.6%24.3%28.1%30.6%23.8%——−24.9%—10.7%27.8%4.0%12.7%15.1%13.6%
R&D as % of revenue4.7%4.7%5.0%5.2%4.8%4.7%4.9%5.6%5.3%6.4%5.9%6.2%5.7%5.6%5.2%
SG&A as % of revenue38.9%41.3%42.2%41.7%38.4%39.8%42.6%41.9%44.3%41.6%39.8%38.4%38.2%39.6%40.3%
Dividends ÷ net income————61.6%10.7%—17.4%—49.8%86.9%19.6%21.7%27.0%23.4%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 6 checks passed · June 30, 2026
What it owns · $22.8bn
Short-term assets $5.1bnLonger-term assets $17.7bn
What it owes, and who funded it · $22.8bn
Short-term liabilities $3.0bnLonger-term liabilities $7.2bnShareholders' equity $12.6bn
  • Short-term assets cover short-term liabilities $5.1bn of assets due within a year against $3.0bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $5.1bn short-term assets against $7.2bn of longer-dated liabilities.
  • More cash than debt $410m of cash against $7.5bn of debt.
  • Debt below 40% of shareholders' equity Debt is 59% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 43% to 59% over five years.
  • A year's operating cash flow covers at least 20% of debt $1.7bn of operating cash flow against $7.5bn of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Zimmer Biomet's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

71 /100

Strong moat

How hard Zimmer Biomet's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 12 / 20

    Cash operating profit has been a median 10.0% of total assets over 10 years.

  • Pricing power 18 / 20

    Gross margin has been a median 70.8%, moving by 4.4 percentage points (standard deviation) across 10 years.

  • Durability 3 / 20

    Operating margin has been a median 13.3%; its worst year was -0.6%.

  • Cash conversion 19 / 20

    Free cash flow was positive in 10 of 10 years, at a median 18.3% of revenue.

  • Discipline 19 / 20

    The diluted share count fell 6.0% over five years; stock-based pay has been a median 1.2% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ALC vs ZBHEW vs ZBHISRG vs ZBHBAX vs ZBH

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Zimmer Biomet's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Zimmer Biomet.